<DOC>
	<DOCNO>NCT02204293</DOCNO>
	<brief_summary>Interleukin-1 antagonist canakinumab use treatment AOSD mark influence activity disease , include joint mobility . Results control clinical study , however , currently available .</brief_summary>
	<brief_title>Canakinumab Treatment Adult Onset Still 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Still 's Disease , Adult-Onset</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Written sign consent patient participate study 2 . Men woman age ≥ 18 year ≤ 75 year 3 . Fulfilment AOSD classification criterion ( accord Yamaguchi et al , J. Rheumatology , 1992 ) 4 . Disease activity base DAS28 ≥3.2 screen 5 . At least 4 painful 4 swollen joint screen baseline ( 28 joint accord DAS28 ) 6 . If undergoing treatment NSAIDs , stable dose least 4 week prior randomisation 7 . If undergoing treatment glucocorticoid , stable dose ≤10 mg/day ( prednisolone equivalent ) least 4 week prior randomisation 8 . If undergoing treatment conventional DMARD , stable dose least 3 month prior randomisation 9 . Normalisation period biological DMARDS ( Anakinra 1 week , Etanercept 1 month , Adalimumab Certolizumab 2 month , Infliximab , Golimumab , Abatacept Tociluzumab 3 month , Rituximab 9 month , canakinumab 6 month ) prior randomisation 10 . In patient reproductive age , use effective method contraception well negative pregnancy test prior study commence . 1 . Previous treatment study drug repeat administration canakinumab 2 . Intraarticular intravenous administration glucocorticoid within 4 week prior baseline use narcotic analgesic except analgesic permit within framework investigation ( Codeine Tramadol ) 3 . Presence another , serious chronicinflammatory disease 4 . Positive Hepatitis B antigen ( HBsAg ) , Hepatitis C antibodies and/or HIV antibody . 5 . Presence relevant , active infection disease , entail tendency towards infection . 6 . Positive screen latent tuberculosis , accordance usual local practice 7 . Raised liver count ( raise bilirubin ; ALT AST ≥3fold normal range ) 8 . Serumcreatinine concentration &gt; 1.5 mg/dl 9 . Inadequate haematological finding ( Hb ≤ 10 g/dl , neutrophils ≤2,500/µl thrombocyte ≤100,000/µl ) 10 . Simultaneous participation interventional clinical study within last 30 day precede commencement study 11 . History neoplasia exception curatively treat nonmelanoma skin tumour carcinoma cervix treat situ without indication recurrence within last 10 year 12 . Relevant cardiac pulmonary disorder 13 . Severe intercurrent neurological psychiatric disorder 14 . Macrophage activation syndrome ( MAS ) part previous treatment IL1 blockade ( e.g . Anakinra , Rilonacept ) 15 . Vaccination live vaccine within 3 month baseline 16 . Alcohol drug abuse past 12 month 17 . ≥400 ml donation blood loss 8 week baseline 18 . Pregnancy breastfeed 19 . Commitment patient institution direction authority court</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Adult-Onset Still´s Disease</keyword>
	<keyword>Canakinumab</keyword>
	<keyword>Joint involvement</keyword>
	<keyword>AOSD</keyword>
</DOC>